Evidence map›Paper›PMID 35039952›Full record

ArticleBreast cancer research and treatment2022

Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer.

Jessica A Martinez, Betsy C Wertheim, Denise J Roe, Pavani Chalasani, Jules Cohen, Lea Baer, H-H Sherry Chow, Alison T Stopeck, Patricia A Thompson

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01761877 (NSAID Effects on Clinical and Imaging Breast Biomarkers), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01761877 phase2completednot on this map

NSAID Effects on Clinical and Imaging Breast Biomarkers

TypeinterventionalSponsorStony Brook UniversityRan2012 to 2019Enrolled114ConditionsInflammation, Cancer, Pain, HypertensionArmsSulindac
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jessica A MartinezUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Betsy C WertheimUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Denise J RoeUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Pavani ChalasaniUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Jules CohenDepartment of Medicine, Stony Brook University, Stony Brook, NY, USA.
Lea BaerDepartment of Medicine, Stony Brook University, Stony Brook, NY, USA.
H-H Sherry ChowUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Alison T Stopeck *Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
Patricia A Thompson *Department of Pathology, Stony Brook University, Stony Brook, NY, USA. Patricia.Thompson@cshs.org.ORCID http://orcid.org/0000-0002-8231-4550
University of Arizona · USStony Brook University · USCedars-Sinai Medical Center · US

Funding

Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer riskR01CA235720 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI STOPECK, ALISON T., THOMPSON, PATRICIA ANN · 2019 to 2024
$3.0M
Nsaid Effects on Clinical and Imaging Breast BiomarkersR01CA161534 · NCI · UNIVERSITY OF ARIZONA · PI STOPECK, ALISON T., THOMPSON, PATRICIA ANN · 2012 to 2016
$2.4M
NCI NIH HHS R01 CA161534NCI NIH HHS R01CA161534NCI NIH HHS R01 CA235720
6 · The paper itself

Abstract

purposeTo examine benefit of sulindac for relief of musculoskeletal symptoms (MSS) in patients stable on aromatase inhibitors (AIs).

methodsSulindac was evaluated at 150 mg twice daily for effects on MSS at 3, 6, 9, and 12 months in 50 postmenopausal women stable on AI therapy for a median of 12.5 months for hormone receptor-positive breast cancer. A separate, non-randomized group of 50 similar patients was observed for change in MSS over 12 months. MSS severity was assessed using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index and Brief Pain Inventory Short Form (BPI-SF). The Functional Assessment of Cancer Therapy-General form (FACT-G) measured quality of life (QOL). Change in MSS and QOL across time was assessed in each group using linear mixed effects models.

resultsStiffness, not pain, was the main complaint at baseline. At 12 months, sulindac patients reported decreases (improvements) in mean (95% CI) Total WOMAC score [- 5.85 (- 9.73, - 1.96)] and WOMAC pain [- 5.40 (- 10.64, - 0 .18)], Stiffness [- 9.53 (- 14.98, - 4.08)] and Physical Function [- 5.61 (- 9.62, - 1.60)] subscales, but not BPI-SF worst pain. Among sulindac patients with higher baseline MSS severity, 35% experienced ≥ 50% improvement in Total WOMAC and Total FACT-G scores [6.18 (2.08, 10.27); P = 0.003]. For the observation group, MSS and QOL did not improve over 12 months, even among those with higher baseline MSS severity.

conclusionsSulindac may relieve MSS in AI patients, especially physical function and stiffness. Randomized controlled trials should further evaluate NSAIDs on AI-MSS and AI adherence. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: NCT01761877, December, 2012.

Indexed as

Aromatase InhibitorsBreast NeoplasmsSulindacFemaleHumansPainQuality of LifeTreatment OutcomeAromatase InhibitorsSulindacAromatase inhibitorBreast cancerMusculoskeletal symptomsNon-steroidal anti-inflammatory drug (NSAID)SulindacWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

Identifiers

PMID35039952
PMCPMC8879419
OpenAlexW4206655975

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.